
Andrea Amalfitano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2145654/publications.pdf Version: 2024-02-01



ANDREA AMALEITANO

#	Article	IF	CITATIONS
1	Adenoviral delivery of an immunomodulatory protein to the tumor microenvironment controls tumor growth. Molecular Therapy - Oncolytics, 2022, 24, 180-193.	4.4	5
2	ERAP1 is a critical regulator of inflammasome-mediated proinflammatory and ER stress responses. BMC Immunology, 2022, 23, 9.	2.2	7
3	SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. Journal of Immunology, 2021, 206, 193-205.	0.8	40
4	Absence of ERAP1 in B Cells Increases Susceptibility to Central Nervous System Autoimmunity, Alters B Cell Biology, and Mechanistically Explains Genetic Associations between ERAP1 and Multiple Sclerosis. Journal of Immunology, 2021, , ji2100813.	0.8	2
5	Δ9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7–Stimulated Human Coculture. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 191-201.	2.5	43
6	lmiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system. Journal of Neuroimmunology, 2019, 333, 576969.	2.3	13
7	The role of ERAP1 in autoinflammation and autoimmunity. Human Immunology, 2019, 80, 302-309.	2.4	17
8	SLAM Family Receptor Signaling in Viral Infections: HIV and Beyond. Vaccines, 2019, 7, 184.	4.4	8
9	SLAMF7 Is a Critical Negative Regulator of IFN-α–Mediated CXCL10 Production in Chronic HIV Infection. Journal of Immunology, 2019, 202, 228-238.	0.8	29
10	In vitro Infection of Primary Human Monocytes with HIV-1. Bio-protocol, 2019, 9, .	0.4	2
11	Compound heterozygosity for loss-of-function <i>FARSB</i> variants in a patient with classic features of recessive aminoacyl-tRNA synthetase-related disease. Human Mutation, 2018, 39, 834-840.	2.5	30
12	ELOVL4-Mediated Production of Very Long-Chain Ceramides Stabilizes Tight Junctions and Prevents Diabetes-Induced Retinal Vascular Permeability. Diabetes, 2018, 67, 769-781.	0.6	41
13	HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-Î ³ -inducible protein 10 levels compared with nonusing HIV patients. Aids, 2018, 32, 419-429.	2.2	78
14	ERAP1 deficient mice have reduced Type 1 regulatory T cells and develop skeletal and intestinal features of Ankylosing Spondylitis. Scientific Reports, 2018, 8, 12464.	3.3	24
15	Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses. Vaccine Journal, 2017, 24, .	3.1	2
16	Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased <i>in utero</i> and perinatal mortality. International Immunology, 2017, 29, 277-289.	4.0	13
17	Current and Future Treatments for Lysosomal Storage Disorders. Current Treatment Options in Neurology, 2017, 19, 45.	1.8	9

18 Methods to Mitigate Immune Responses to Adenoviral Vectors. , 2016, , 391-422.

2

#	Article	IF	CITATIONS
19	CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets. Vaccine, 2016, 34, 3109-3118.	3.8	6
20	In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens. Journal of Immunology, 2016, 196, 1741-1752.	0.8	13
21	Recent advances in gene therapy for lysosomal storage disorders. The Application of Clinical Genetics, 2015, 8, 157.	3.0	36
22	Autoimmune Disease-Associated Variants of Extracellular Endoplasmic Reticulum Aminopeptidase 1 Induce Altered Innate Immune Responses by Human Immune Cells. Journal of Innate Immunity, 2015, 7, 275-289.	3.8	40
23	Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination. Cancer Immunology, Immunotherapy, 2015, 64, 479-491.	4.2	2
24	Stimulation of Innate Immunity by <i>In Vivo</i> Cyclic di-GMP Synthesis Using Adenovirus. Vaccine Journal, 2014, 21, 1550-1559.	3.1	12
25	ERAP1 functions override the intrinsic selection of specific antigens as immunodominant peptides, thereby altering the potency of antigen-specific cytolytic and effector memory T-cell responses. International Immunology, 2014, 26, 685-695.	4.0	16
26	Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy. International Immunology, 2014, 26, 291-303.	4.0	13
27	Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19890-19895.	7.1	107
28	Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens. Autoimmunity, 2013, 46, 497-508.	2.6	56
29	Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2013, 62, 1293-1301.	4.2	76
30	Activation of human natural killer cells by the novel innate immune modulator recombinant Eimeria antigen. Human Immunology, 2013, 74, 916-926.	2.4	6
31	Endoplasmic Reticulum Aminopeptidase-1 Functions Regulate Key Aspects of the Innate Immune Response. PLoS ONE, 2013, 8, e69539.	2.5	41
32	Response to Reuser. Genetics in Medicine, 2012, 14, 827-828.	2.4	18
33	Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine, 2012, 30, 1492-1501.	3.8	29
34	Malaria vaccines: Focus on adenovirus based vectors. Vaccine, 2012, 30, 5191-5198.	3.8	32
35	Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells. Molecular Genetics and Metabolism, 2012, 105, 677-680.	1.1	59
36	Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naà ve and Adenovirus (Ad5) immune mice. Malaria Journal, 2012, 11, 209.	2.3	11

#	Article	IF	CITATIONS
37	Vaccines Expressing the Innate Immune Modulator EAT-2 Elicit Potent Effector Memory T Lymphocyte Responses despite Pre-Existing Vaccine Immunity. Journal of Immunology, 2012, 189, 1349-1359.	0.8	15
38	Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects. Current Pharmaceutical Design, 2011, 17, 2558-2574.	1.9	32
39	Use of DAF-Displaying Adenovirus Vectors Reduces Induction of Transgene- and Vector-Specific Adaptive Immune Responses in Mice. Human Gene Therapy, 2011, 22, 1083-1094.	2.7	11
40	Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity. Vaccine Journal, 2011, 18, 150-160.	3.1	44
41	Cutting Edge: Coding Single Nucleotide Polymorphisms of Endoplasmic Reticulum Aminopeptidase 1 Can Affect Antigenic Peptide Generation In Vitro by Influencing Basic Enzymatic Properties of the Enzyme. Journal of Immunology, 2011, 186, 1909-1913.	0.8	122
42	Expression of the SLAM Family of Receptors Adapter EAT-2 as a Novel Strategy for Enhancing Beneficial Immune Responses to Vaccine Antigens. Journal of Immunology, 2011, 186, 722-732.	0.8	32
43	TRIF Is a Critical Negative Regulator of TLR Agonist Mediated Activation of Dendritic Cells In Vivo. PLoS ONE, 2011, 6, e22064.	2.5	12
44	Vaccine Platforms Combining Circumsporozoite Protein and Potent Immune Modulators, rEA or EAT-2, Paradoxically Result in Opposing Immune Responses. PLoS ONE, 2011, 6, e24147.	2.5	13
45	Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector–triggered immune responses in vitro and in vivo. Blood, 2010, 116, 1669-1677.	1.4	37
46	A New Adenovirus Based Vaccine Vector Expressing an Eimeria tenella Derived TLR Agonist Improves Cellular Immune Responses to an Antigenic Target. PLoS ONE, 2010, 5, e9579.	2.5	33
47	Improving Adenovirus Based Gene Transfer: Strategies to Accomplish Immune Evasion. Viruses, 2010, 2, 2013-2036.	3.3	20
48	Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opinion on Biological Therapy, 2009, 9, 1521-1531.	3.1	81
49	Transient Pretreatment With Glucocorticoid Ablates Innate Toxicity of Systemically Delivered Adenoviral Vectors Without Reducing Efficacy. Molecular Therapy, 2009, 17, 685-696.	8.2	99
50	A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunology Letters, 2009, 122, 44-51.	2.5	36
51	Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine, 2009, 27, 6394-6398.	3.8	44
52	Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology, 2008, 374, 453-467.	2.4	30
53	Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Research, 2008, 132, 1-14.	2.2	204
54	Adenovirus Vector-Induced Innate Inflammatory Mediators, MAPK Signaling, As Well As Adaptive Immune Responses Are Dependent upon Both TLR2 and TLR9 In Vivo. Journal of Immunology, 2008, 181, 2134-2144.	0.8	174

#	Article	IF	CITATIONS
55	Adenovirus Infection Triggers a Rapid, MyD88-Regulated Transcriptome Response Critical to Acute-Phase and Adaptive Immune Responses In Vivo. Journal of Virology, 2007, 81, 1796-1812.	3.4	135
56	Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology, 2007, 358, 357-372.	2.4	77
57	Fully Deleted Adenovirus Persistently Expressing GAA Accomplishes Long-Term Skeletal Muscle Glycogen Correction in Tolerant and Nontolerant GSD-II Mice. Molecular Therapy, 2006, 13, 127-134.	8.2	42
58	Multiple Innate Inflammatory Responses Induced after Systemic Adenovirus Vector Delivery Depend on a Functional Complement System. Molecular Therapy, 2006, 14, 588-598.	8.2	96
59	Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. Journal of Gene Medicine, 2005, 7, 171-178.	2.8	30
60	Utilization of adenovirus vectors for multiple gene transfer applications. Methods, 2004, 33, 173-178.	3.8	30
61	Molecular Therapy: The Journal of the American Society of Gene Therapy Gene Function and Disease. JAMA - Journal of the American Medical Association, 2003, 289, 622.	7.4	1
62	Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities. Current Opinion in Molecular Therapeutics, 2003, 5, 362-6.	2.8	4
63	Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) Is Critically Dependent on Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector Transduction. Molecular Therapy, 2002, 5, 436-446.	8.2	62
64	Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy. Current Gene Therapy, 2002, 2, 111-133.	2.0	123
65	Dystrophin Expression in Muscle Following Gene Transfer with a Fully Deleted ("Gutted") Adenovirus Is Markedly Improved by Trans-Acting Adenoviral Gene Products. Human Gene Therapy, 2001, 12, 1741-1755.	2.7	56
66	Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. Journal of Gene Medicine, 2000, 2, 250-259.	2.8	57
67	Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. , 2000, 2, 250.		2
68	Persistence of an [E1-, Polymerase-] Adenovirus Vector Despite Transduction of a Neoantigen into Immune-Competent Mice. Human Gene Therapy, 1999, 10, 355-364.	2.7	57
69	Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted. Journal of Virology, 1998, 72, 926-933.	3.4	234